These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 11471896)
1. Cytokeratins as serum markers in egyptian bladder cancer. A comparison of CYFRA 21-1, TPA and TPS. Mady EA Int J Biol Markers; 2001; 16(2):130-5. PubMed ID: 11471896 [TBL] [Abstract][Full Text] [Related]
2. Comparison of CYFRA 21-1, TPA and TPS in lung cancer, urinary bladder cancer and benign diseases. Stieber P; Dienemann H; Hasholzner U; Fabricius PG; Schambeck C; Weinzierl M; Poley S; Samtleben W; Hofmann K; Meier W Int J Biol Markers; 1994; 9(2):82-8. PubMed ID: 7523546 [TBL] [Abstract][Full Text] [Related]
3. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinoma. Huang MS; Jong SB; Tsai MS; Lin MS; Chong IW; Lin HC; Hwang JJ Respir Med; 1997 Mar; 91(3):135-42. PubMed ID: 9135852 [TBL] [Abstract][Full Text] [Related]
4. Cytokeratin tumor marker levels in bronchial washing in the diagnosis of lung cancer. Trevisani L; Putinati S; Sartori S; Abbasciano V; Bagni B Chest; 1996 Jan; 109(1):104-8. PubMed ID: 8549168 [TBL] [Abstract][Full Text] [Related]
5. Comparative sensitivity of urinary CYFRA 21-1, urinary bladder cancer antigen, tissue polypeptide antigen, tissue polypeptide antigen and NMP22 to detect bladder cancer. Sánchez-Carbayo M; Herrero E; Megías J; Mira A; Soria F J Urol; 1999 Dec; 162(6):1951-6. PubMed ID: 10569545 [TBL] [Abstract][Full Text] [Related]
6. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and tissue polypeptide specific antigen (TPS) as tumour markers in lung cancer. Stieber P; Dienemann H; Hasholzner U; Müller C; Poley S; Hofmann K; Fateh-Moghadam A Eur J Clin Chem Clin Biochem; 1993 Oct; 31(10):689-94. PubMed ID: 7507359 [TBL] [Abstract][Full Text] [Related]
7. Clinical relevance of CYFRA 21-1, TPA-IRMA and TPA-LIA-mat in urinary bladder cancer. Stieber P; Schmeller N; Schambeck C; Hofmann K; Reiter W; Hasholzner U; Fateh-Moghadam A Anticancer Res; 1996; 16(6B):3793-8. PubMed ID: 9042259 [TBL] [Abstract][Full Text] [Related]
8. Comparison of CYFRA 21-1 and tissue polypeptide specific antigen (TPS) for detecting nasopharyngeal carcinoma. Tai CJ; Liu FY; Liang JA; Yang SN; Tsai MH; Kao CH Anticancer Res; 2002; 22(6B):3793-6. PubMed ID: 12552995 [TBL] [Abstract][Full Text] [Related]
9. Comparison of Cyfra 21-1, TPA and SCC tumor markers in esophageal squamous cell carcinoma. Quillien V; Raoul JL; Laurent JF; Meunier B; Le Prise E Oncol Rep; 1998; 5(6):1561-5. PubMed ID: 9769406 [TBL] [Abstract][Full Text] [Related]
10. Serum TPS versus TPA in Egyptian bladder cancer patients. Halim AB; el-Ahmady O; Hamza S; Aboul-Ela M; Oehr P Int J Biol Markers; 1993; 8(4):221-6. PubMed ID: 7511149 [TBL] [Abstract][Full Text] [Related]
11. The clinical value of CYFRA21-1 in bladder cancer patients: Egyptian experience. el-Ahmady O; Halim AB; el-Din AG Anticancer Res; 1999; 19(4A):2603-8. PubMed ID: 10470202 [TBL] [Abstract][Full Text] [Related]
12. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen. Bonfrer JM; Gaarenstroom KN; Korse CM; Van Bunningen BN; Kenemans P Anticancer Res; 1997; 17(3C):2329-34. PubMed ID: 9245246 [TBL] [Abstract][Full Text] [Related]
13. Determination of serum levels of different cytokeratins in patients with uterine malignancies. Ferdeghini M; Gadducci A; Prontera C; Castellani C; Annicchiarico C; Gagetti O; Facchini V; Bianchi R Anticancer Res; 1994; 14(3B):1393-7. PubMed ID: 7520682 [TBL] [Abstract][Full Text] [Related]
14. Cytokeratin-19 fragment (CYFRA 21-1) in bladder cancer. Morita T; Kikuchi T; Hashimoto S; Kobayashi Y; Tokue A Eur Urol; 1997; 32(2):237-44. PubMed ID: 9286660 [TBL] [Abstract][Full Text] [Related]
15. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer. Lai RS; Hsu HK; Lu JY; Ger LP; Lai NS Chest; 1996 Apr; 109(4):995-1000. PubMed ID: 8635383 [TBL] [Abstract][Full Text] [Related]
16. Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA- TP CEA, and NSE. Ebert W; Hoppe M; Muley T; Drings P Anticancer Res; 1997; 17(4B):2875-8. PubMed ID: 9329552 [TBL] [Abstract][Full Text] [Related]
17. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer. Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660 [TBL] [Abstract][Full Text] [Related]
18. Cytokeratins as serum markers in lung cancer: a comparison of CYFRA 21-1 and TPS. Pujol JL; Grenier J; Parrat E; Lehmann M; Lafontaine T; Quantin X; Michel FB Am J Respir Crit Care Med; 1996 Sep; 154(3 Pt 1):725-33. PubMed ID: 8810612 [TBL] [Abstract][Full Text] [Related]
19. Prospective study of a panel of tumor markers as prognostic factors in patients with squamous cell carcinoma of head and neck. Kandiloros D; Eleftheriadou A; Chalastras T; Kyriou L; Yiotakis I; Ferekidis E Med Oncol; 2006; 23(4):463-70. PubMed ID: 17303904 [TBL] [Abstract][Full Text] [Related]
20. Measurements of free and total PSA, tissue polypeptide-specific antigen (TPS), and CYFRA 21-1 in prostate cancer patients under intermittent androgen suppression therapy. Theyer G; Dürer A; Theyer U; Haberl I; Ulsperger E; Baumgartner G; Hamilton G Prostate; 1999 Oct; 41(2):71-7. PubMed ID: 10477903 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]